B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
/ 2 items
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
EyePoint DURAVYU misses primary endpoint in LUGANO Phase 3 for wet AMD. Strong secondaries: 42% treatment burden reduction, favorable safety.